IGF1R and pulmonary arterial hypertension: Repurposing and Novel Agents: A pragmatic strategy involves the rapid evaluation of existing IGF-1R inhibitors (e.g., linsitinib from oncology) in pre-clinical PAH models (Gulbins et al., 2023).